Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology and contemplate a private placement of NOK 125-150 million to fund the combined business.
The Board of Directors convenes an extraordinary general meeting of Targovax AS on Monday, 22 June 2015, at 15:00 hours (CET) at the company’s premises in Vollsveien 6, NO-1366 Lysaker to treat matters related to the transaction.
Please find the notice of the meeting attached (pdf)